Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Curetis en de Yorkville-dumpfabriek
Volgen
1Curetis Elects Share Settlement for Excess Entitlement Under First Tranche of Yorkville Convertible Notes-Share issue cap of 2.75 million shares under the first tranche of EUR 5 million in Yorkville convertible bonds has been reached-Curetis elects tosettle the excess entitlement under the first tranche in sharesElements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, USA, August1, 2019,8:00 am CEST –In its press release dated October 2, 2018, Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, announced thatit secured up to EUR 20 million in growth capital through the issuance of convertible notes by the Companywith share subscription warrants to YA II PN, Ltd, an investment fund managed by Yorkville Advisors Global LP, a U.S.-based management firm (the “Investor” or “Yorkville”),and that it had drawn down EUR 3.5 million of the first tranche of EUR 5 million by issuing convertible notes. On May 21, 2019, the Companyannounced that it had drawn down the remainder of the first tranche (i.e. EUR 1.5 million).To date, Yorkville has issued several conversion notices to convert part of the notes held by it into equity for whichthe Companyhas issued new shares. Under the terms of the agreement, the number of shares to be issued upon conversion of all convertible notes of the first tranche shall not exceed 2.75 million shares (the “First Tranche Share Issue Cap”). Any excess entitlement on the basis of the conversion ratio will be settled in cash unless the Company elects to settle such excess in shares. Yesterdayevening, the Companyreceived a further conversion noticefrom Yorkvillewhich, if fully settled in shares, would result inthe First Tranche Share Issue Cap beingexceeded. The Company will settle its obligations resulting from thisconversion notice fully in shares, thereby exercising its right under the agreement with Yorkville to settle the excess beyond the First Tranche Share Issue Capin shares. TheCompanyalso intendstoelect settlement fully in shares in respect of any furtherconversion of the remaining notes held byYorkville.The shares issued by the Company upon conversion of the first tranche of convertible notes subscribed for by Yorkville up to theFirst TrancheShare Issue Cap have been and, to the extent still available, will be issued pursuant to the authorization granted at the Company’s Annual General Meeting held on June 21, 2018 (the “2018 AGM”), which designated the Company’s management board, subject to the approval of the Company’s supervisory board, as the corporate body authorized to issue shares and/or grant rights to subscribe for shares in relation to strategic capital raising(s) and to limit or exclude pre-emption rights relating thereto. Any shares issued by the Company upon conversion of the first tranche of convertiblenotes subscribed for by Yorkville to settle any excess beyond the First Tranche Share Issue Capwill beissued pursuant to the 10% authorization granted at the Company’s Annual General Meetingheld on June 27, 2019(the “2019 AGM”), which designated the Company’s management board, subject to the approval of the Company’s supervisory board, as the corporate body authorized to issue shares and/or grant rights to subscribe 2for shares in relation to general capital raising(s) and to limit or exclude pre-emption rights relating thereto. The Company may thereafter be required to seek from its shareholders further authorizations to issue additional shares upon conversion of subsequent tranches of notes and exercise of warrants prior to the funding of such subsequent tranches, based upon certain coverage requirements specified in the agreement. For the avoidance of doubt, the Company’s management board has further authorizations (i) to issue, without pre-emption rights, up to approximately 2.25 million further shares and/or rights to subscribe for shares pursuant to the authorizations granted by the 2019 AGM, but the Company may only use such authority in relation to mergers and acquisitions or strategic alliances, and (ii) to issue, with pre-emption rights, up to approximately 11.23 million further shares and/or rights to subscribe for shares pursuant to the authorizations granted by the 2019 AGM, with a view to raise additional capital to support the execution of the Company’s revised strategy and the development ofits business. For further details on the Yorkville convertible notes facility, please also see the “Convertibles” section under: curetis.com/investors
Curetis N.V. Hieronder vindt u informatie uit het register geplaatst kapitaal uitgevende ondernemingen. Deze informatie is door de organisatie verstrekt. Datum meldingsplicht 06 aug 2019 Uitgevende instelling Curetis N.V. Inschrijving handelsregister 64302679 Plaats Holzgerlingen Totale kapitaalverdeling Maand Totaal geplaatst kapitaal Totaal aantal stemmen 246.233,97 EUR 24.623.397,00 Vorige melding Soort aandeel Nominale waarde Aantal geplaatst Aantal stemmen per aandeel Aantal gecertificeerd Gewoon aandeel 0,01 22.917.973 1,00 0 -------------------------------------------------------------------------- Nieuwe melding Soort aandeel Nominale waarde Aantal geplaatst Aantal stemmen per aandeel Aantal gecertificeerd Gewoon aandeel 0,01 24.623.397 1,00 0 Datum laatste update: 10 augustus 2019
Yorkville heeft dus weer ca 1,7 miljoen aandelen gedumpt of is daar nog mee bezig. En dat is gebeurt sinds 19 juli.
Curetis N.V. Hieronder vindt u informatie uit het register geplaatst kapitaal uitgevende ondernemingen. Deze informatie is door de organisatie verstrekt. Datum meldingsplicht 19 jul 2019 Uitgevende instelling Curetis N.V. Inschrijving handelsregister 64302679 Plaats Holzgerlingen ---------------------------------------------------------------------- Totale kapitaalverdeling Maand Totaal geplaatst kapitaal Totaal aantal stemmen 229.179,73 EUR 22.917.973,00 ------------------------------------------------------------------------ Vorige melding Soort aandeel Nominale waarde Aantal geplaatst Aantal stemmen per aandeel Aantal gecertificeerd Gewoon aandeel 0,01 22.572.062 1,00 0 ----------------------------------------------------------------------- Nieuwe melding Soort aandeel Nominale waarde Aantal geplaatst Aantal stemmen per aandeel Aantal gecertificeerd Gewoon aandeel 0,01 22.917.973 1,00 0
Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville-Curetis and EIB agree on equity-linked participation upon maturity of new EUR 5 million tranche of debt financing-Yorkville to provide funding of EUR 1.5 million to Curetis Amsterdam, the Netherlands, and Holzgerlingen, Germany, May 21, 2019--Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that Curetis will receive another EUR 6.5 million in gross proceeds under two financing facilities. Firstly, under the EIB debt financing facility originally put in place in December 2016, Curetis now stands to receive another EUR 5.0 million tranche of non-dilutive debt financing. This tranche will also have a five-year term to maturity and will require interest-only payments during that five-year term. In line with all prior tranches,the majority of interest is also deferred into the bullet repayment structure upon maturity. In return for EIB waiving certain conditions precedent to disbursing this EUR 5 million tranche, the parties have agreed on a 2.1% participation percentage interest (PPI). Upon maturityof the tranche, i.e. not beforearound mid-2024 (and no later than mid-2025), EIB will be entitled to an additional payment that is equity-linked and equivalent to 2.1% of the then total valuation of Curetis. All other terms and conditions of the EIB financing contract with Curetis remain unchanged. Secondly, under the up to EUR 20 million Yorkville convertible notes financing facilitythat was originally implemented in October 2018, Curetis has now received access to another EUR 1.5 million gross in fundingsubject to having received the aforementioned EUR 5 million tranche from EIB. Net proceeds from this tranche are expected to be about EUR 1.36million. As with the prior tranche, Yorkville is expected from time to time to convert such notes into equity and Curetis will then issue new shares. For further details on the Yorkville convertible notes facility,please also see the “Convertibles” section under: curetis.com/investors/#corporate-gove... are pleased to see continued support and funding from both EIB and Yorkville,” said Oliver Schacht, PhD, CEO of Curetis. “The additional funding will allow Curetis to continue executing on its R&D programs such as the Unyvero A30 RQplatform development towards partnering, the Unyvero LRT for BAL specimenin the US, as well as the Ares Genetics R&D programs.The Yorkville funding will also support commercial activities in the US and business development initiatives in Europeand Asia.
Curetis has now received access to another EUR 1.5 million gross in fundingsubject to having received the aforementioned EUR 5 million tranche from EIB. Net proceeds from this tranche are expected to be about EUR 1.36million Hier kunnen we precies zien wat Yorkville verdient met het dumpen van de aandelen: Yorkville krijgt een winstmarge van 140.000 op een bedrag van 1,5 miljoen; dat is dus bijna 10% winst.
Hier vind je informatie over andere Yorkville-dumps:www.iex.nl/Forum/Topic/1267070/1/Alle...
DeZwarteRidder schreef op 10 augustus 2019 10:50 :
Hier vind je informatie over andere Yorkville-dumps:
www.iex.nl/Forum/Topic/1267070/1/Alle... Lijst het in en zet het op je bureau. Geld lenen om een overbrugging naar een bepaald doel te realiseren kost geld, jij doet of dat abnormaal is, maar het is net zo normaal al brood bij de bakker kopen.
lucas D schreef op 10 augustus 2019 11:55 :
[...]
Lijst het in en zet het op je bureau.
Geld lenen om een overbrugging naar een bepaald doel te realiseren kost geld, jij doet of dat abnormaal is, maar het is net zo normaal al brood bij de bakker kopen.
Helaas voor de aandeelhouders is Curetis een bodemloze put.
DeZwarteRidder schreef op 10 augustus 2019 12:29 :
[...]
Helaas voor de aandeelhouders is Curetis een bodemloze put.
Zet het op een tegeltje, dan kan je bij elk ander forum waar je 'kennis' deelt de naam er bij invullen.
Hier staan de kleine lettertjes over de zogenaamde convertibles en Yorkville:curetis.com/wp-content/uploads/Cureti...
Conversion ratio Upon a Conversion the number of newShares issuedby the Issuer to the relevantNote holder in accordance with Paragraphs 8.1 and 8.2 of this Schedule 2 will be calculated as the Conversion Amount divided by 93% of the Market Price on the applicable Conversion Date (the “Conversion Price”).The Conversion Price will be determined to two decimals places and rounded down to the nearest 100th.If the issuance of new Shares would result in the issuance of a fraction of a Share, the Issuer shall round such fraction of a Share down to the nearest whole Share.The aggregate nominal value of the Shares to be issued upon a Conversion shall be paid up by way of set-off against the aggregate Conversion Amount, with the difference being treated as unstipulated share premium. The Issuer shall promptly deliver freely tradable Shares to the relevant Note holder upon each Conversion of Note(s), it being specified that, in any case, the reception of the Shares, by the relevant Note holder shall occur no later than three (3) Trading Days after the Conversion Date.Upon Conversion of Notes, if the relevant Note holder does not receive the relevant Shares as provided for in the paragraph above, and if no early redemption of the Notes was requested by the relevant Note holder, at the Note holder’s discretion, the Issuer shall pay to the relevant Note holder an amount equal to the difference (if positive) between the closing price of the Share on Euronext in Amsterdam on the Conversion Date and the closing price of the Share on Euronextin Amsterdamon the day immediately prior to the date on which the relevant Shares are effectively received by the relevant Note holder, for each new Share which was issued upon the relevant Conversion of Notes.If the Issuer is unable to issue the number of Shares required upon a Conversion due tothe Issuer not having sufficient shareholders’ authorizations or sufficient authorized capital under its By-laws, and if noearly redemption of the Notes was requested by the relevant Note holder, the Issuer shall have the obligation to satisfy the number of Shares which it is unable to issue upon Conversion in cash, by paying to the Note holder, within three(3) Trading Days following the ConversionDate,an amount equal to the number of Shares it is not able to issue multiplied by the closing Share price on Euronext in Amsterdam on the Conversion Date.
Yorkville krijgt dus een vaste korting op de aandelen van 7% (zie boven).
[Modbreak IEX: Gelieve inhoudelijk te reageren, bericht is bij dezen verwijderd.]
DeZwarteRidder bedankt voor de info in dit draadje, het meeste ken ik al. Wel heb ik het convertible (23 pagina's met de kleine letters) nog even doorgenomen. Voor mij persoonlijk geen beletsel om maandag mijn positie verder uit te breiden. Rick.
Fischer-R schreef op 11 augustus 2019 15:46 :
DeZwarteRidder bedankt voor de info in dit draadje, het meeste ken ik al. Wel heb ik het convertible (23 pagina's met de kleine letters) nog even doorgenomen. Voor mij persoonlijk geen beletsel om maandag mijn positie verder uit te breiden.
Rick.
Jammer voor je....!! Helaas voor de aandeelhouders wordt dit de 'opvolger' van Esperite.
Bij gelegenheid koop ik er ook nog een paar. Ik ben ook gebaat met een hogere koers. Dat de EIB geld investeert in dit bedrijf geeft toch nog wel een beetje vertrouwen. Pharming heef het ook gered.
Wat staat er te gebeuren bij Curetis? Uitstel cijfers ivm overleg met Amerikaanse bank. Waarover? Extra financiering, extra deelnemers ih bedrijf, overname? Joost mag het weten. Vraag is waarom loopt de koers op? Weten sommigen meer dan wij kleine aandeelhouders? Prijsopdrijving zodat aandelen verkocht kunnen worden?
CuretisRetains H.C. Wainwright& Co. as Strategic Advisor-Investment bank supportsCuretis in assessment of all strategic and tactical financing options -Publication ofH1-2019 financials postponed to September18,2019-Key financials show EUR 7.8 million cash as of June30, 2019and significantly reduced cash burn in H1-2019 Elements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.Amsterdam, the Netherlands, and Holzgerlingen, Germany, August 12,2019, 08:00 am CET-Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has retained the U.S. based investment bank,H.C. Wainwright & Co., LLC,as strategic advisor in an effort to assess all available strategic and tactical options going forward to potentially secure appropriate funding and cash for continued operations for at least the nexttwelve months. Potential strategic options that may be explored or evaluated as part of H.C.Wainwright’smandate may include, but are not limited to,equity funding, an acquisition, merger, business combination or other strategic transaction involving Curetis. There is no definitive timeline for completion of the assessment process and there can beno assurance that the assessmentwouldactually result in Curetispursuing any transaction at all or that a transaction,if it were pursued,could be completed successfully. Curetisdoes not intend to discuss or disclose further developments regarding the strategic assessmentprocess unless and until its supervisory board and its management board haveapproved a specific course of action or otherwise determined that further disclosure is appropriate or required by applicable laws or regulations. As part of its ordinary course of business and regularinvestor relations efforts,the Company will be present at the 21stAnnual H.C. Wainwright Global Life Sciences Conferenceto be held in New York, NY, USA, on September8-10, 2019.In the context of the ongoing strategic assessment, the Company also announced that it will reschedule the publication of its 2019 First Half-Year Business and Financial Update and H1-2019 Earnings Call from its originalfinancial calendar date on August14,2019to September 18,2019.This allows for an ongoing review of H1-2019 financials by the Company’s auditors,especially in light of a series of important new IFRS standards that are now applicable,such as IFRS 16“Leases”.The Company, however, hereby reports certain preliminary, non-audited financials for the first half of 2019. Cash and cash equivalents as atJune30, 2019, amounted to EUR 7.8million.This includes a further EUR 5.0million tranche undera debt financing facility provided by the European Investment Bank (EIB)and the drawdown of the remainder of the first tranche (i.e. EUR 1.5 million(gross))undera convertible notesfacility provided by YA II PN, Ltd, an investment fund managed by Yorkville Advisors Global LP, both as previously announced on May 21, 2019.Cash burn from operations and investments in H1-2019 has been reduced by 25.7%year-over-year as a consequence of the successful implementation of certain corporate reorganization measures.The worldwide installed base of Unyvero A50 Analyzers as atJune 30, 2019, was 170, compared to162as atJune 30, 2018 .This figure includes a significantly sizedpool of Analyzers now managed by Menarini Diagnostics in EMEA (9 new installations have already been identifiedfor H2-2019) as well as 37 Analyzers installed in the USA(including 20 for current and future clinical trials). Furthermore,as part of a campaign performed towards the end ofQ2-2019,a total of 10 refurbished Unyvero Systems were ordered by various international distribution partners with most of them being sold and shipped in H2-2019.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee